Flow-based human tissue models show stronger T-cell activity than static cultures, with blinatumomab inducing significant B-cell killing and cytokine release. Sartorius has introduced a 96-well multi-organ tox plate for drug toxicity testing, while in vitro systems are increasingly used as new approach methodologies to complement animal models.
A study of 450 mTNBC patients in community practices found high biomarker testing rates and encouraging outcomes across racial groups, with Hispanic patients showing the longest survival. However, Black women of West African ancestry face the highest TNBC incidence and greater neuropathy from paclitaxel, making docetaxel a potential alternative. Social determinants like neighborhood deprivation and allostatic load are also linked to TNBC risk.
The FDA has cleared Telomir Pharmaceuticals' IND for Telomir-Zn in advanced or metastatic triple-negative breast cancer. The company plans to initiate a first-in-human Phase 1/2 trial in the first half of 2026.
Intensity Therapeutics restarted its INVINCIBLE-4 Phase 2 trial of INT230-6 in presurgical triple-negative breast cancer, reporting 71.4% pCR with INT230-6 plus SOC versus 33% with SOC alone. 2025 cash stood at $11.9M with runway into Q2 2027.
Atezolizumab plus capecitabine showed no significant survival benefit in residual TNBC. Other reports covered HER2-low AR enrichment, first-line ADC choices, and a self-management planner.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Datopotamab deruxtecan improved PFS and OS versus chemotherapy in advanced TNBC in TROPION-Breast02. Median PFS was 10.8 vs 5.6 months; OS was 23.7 vs 18.7 months. Published in Annals of Oncology.
Research reveals how ectopic NMDA receptor expression in triple-negative breast cancer triggers autoimmune disease through antibody maturation. The study shows NMDAR expression recruits B cells and drives affinity maturation, producing antibodies that can cross the blood-brain barrier and cause neurological symptoms while constraining tumor growth.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07623577 |
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases |
RECRUITING | PHASE2 |
| NCT07622836 |
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. |
RECRUITING | NA |
| NCT07552181 |
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07536815 |
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) |
AVAILABLE | |
| NCT07491822 |
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer |
NOT_YET_RECRUITING | NA |
| NCT07441512 |
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07376629 |
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07021261 |
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients |
NOT_YET_RECRUITING | PHASE3 |
| NCT07017673 |
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer |
RECRUITING | PHASE2 |
| NCT06991790 |
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration |
RECRUITING |
